Study on the Rule and Mechanism of Treating Functional Gastrointestinal Diseases From the Perspective of Liver and Spleen

NCT ID: NCT04454996

Last Updated: 2020-07-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-06-25

Study Completion Date

2022-03-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To clarify the changes of intestinal flora - gut - brain axis in FGIDs patients represented by NERD disharmony of liver and stomach and IBS-D disharmony of liver and spleen, and confirm that the imbalance between intestinal flora and host co-metabolism is the key to the pathogenesis of functional gastrointestinal disease. To reveal the common mechanism of regulating liver and spleen (stomach) in treating FGIDs dynamic disorder and visceral hypersensitivity by regulating intestinal flora - intestine - brain axis disorder.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-erosive Reflux Disease/Diarrheal Irritable Bowel Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Non-erosive reflux disease test group

Group Type EXPERIMENTAL

tong-jiang granules

Intervention Type DRUG

This is a kind of compound Chinese medicine granules, 1 bag each time, 3 times a day, treatment for 4 weeks.

Non-erosive reflux disease control group

Group Type PLACEBO_COMPARATOR

The placebo of tong-jiang granules

Intervention Type DRUG

This is a granule, containing 5% tongyu granule active drug,1 bag each time, 3 times a day, treatment for 4 weeks.

Diarrhea-type irritable bowel syndrome test group

Group Type EXPERIMENTAL

Chang 'an II Recipe

Intervention Type DRUG

This is Chang 'an II Prescription granule, 1 bag each time, 3 times a day, treatment for 4 weeks.

Control group with diarrheal irritable bowel syndrome

Group Type PLACEBO_COMPARATOR

The placebo of Chang 'an II Recipe

Intervention Type DRUG

This is a granule containing 5% chang 'an II,1 bag each time, 3 times a day, treatment for 4 weeks.

Healthy control group

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

tong-jiang granules

This is a kind of compound Chinese medicine granules, 1 bag each time, 3 times a day, treatment for 4 weeks.

Intervention Type DRUG

Chang 'an II Recipe

This is Chang 'an II Prescription granule, 1 bag each time, 3 times a day, treatment for 4 weeks.

Intervention Type DRUG

The placebo of tong-jiang granules

This is a granule, containing 5% tongyu granule active drug,1 bag each time, 3 times a day, treatment for 4 weeks.

Intervention Type DRUG

The placebo of Chang 'an II Recipe

This is a granule containing 5% chang 'an II,1 bag each time, 3 times a day, treatment for 4 weeks.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy volunteers with no abnormal clinical manifestations;
2. Meet the diagnostic criteria of NERD syndrome of disharmony of liver and stomach and IBS-D syndrome of liver depression and spleen deficiency.
3. Aged between 18 and 70.
4. Did not take antibiotics, steroids or other hormones, Chinese herbal preparations (including oral and intravenous administration), microecological preparations or probiotics such as yogurt for nearly a week;
5. Subjects are informed and sign informed consent voluntarily;
6. Have certain reading ability.

Exclusion Criteria

1. Patients with severe lesions of the heart, liver, kidney and other major organs, hematopoietic system, nervous system or mental diseases;
2. Complicated with other organic diseases of the digestive system (such as peptic ulcer), or systemic diseases that affect the dynamics of the digestive tract (such as hyperthyroidism and diabetes);
3. Ongoing or ongoing use of drugs that may affect gastrointestinal function (antidiarrals, antidepressants, anti-anxiety drugs, intestinal microflora regulation drugs, antibiotics, etc.);
4. Those with a history of allergy to related drugs or severe food allergy used in the research.
5. The body is colonized with metal medical devices. (6) Having a pregnancy plan within three months.

\-
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Xiyuan Hospital of China Academy of Chinese Medical Sciences

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Xiyuan Hospital of China Academy of Chinese Medical Science

Beijing, Beijing Municipality, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

lin lv

Role: CONTACT

18811782728

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

lin lv

Role: primary

18811782728

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ZZ13-ZD-02

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Acupuncture for Patients With Function Dyspepsia
NCT01671670 COMPLETED PHASE2/PHASE3
Functional GI Disease Registry
NCT05295446 ENROLLING_BY_INVITATION